Saturday, 23 January 2016 09:23

Anticoagulation news items. Weeks commencing 18th January 2016

Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial

The Lancet Haematology

In this phase 2a proof-of concept trial (n=36) patients with livedoid vasculopathy and minimum pain score of 40 on the visual analogue scale (VAS) received rivaroxaban. Median pain decreased from VAS 65.0 at baseline to 6.0 at 12 weeks treatment (p<0.0001).

 

Bivalirudin in the treatment of acute coronary syndrome

British Medical Journal

This review covers the evidence and clinical implications for use of bivalirudin as an anticoagulant in Percutaneous Coronary Intervention and compares efficacy and outcome data with that of heparin.

 

Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies

British Medical Journal

In this meta-analysis of 30 studies (n=4,371,714) atrial fibrillation was associated with a higher risk of all cause mortality, stroke, CV mortality, and CV events in women compared with men; however, it was noted that further research is needed to confirm causality.

 

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services